

U.S. Postal Service STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION <i>Required by 39 U.S.C. 3685</i>			
1A. TITLE OF PUBLICATION PHARMACOLOGICAL REVIEWS		1B. PUBLICATION NO. 0 0 3 1 6 9 9 7	2. DATE OF FILING 10/1/87
3. FREQUENCY OF ISSUE Quarterly		3A. NO. OF ISSUES PUBLISHED ANNUALLY 4	3B. ANNUAL SUBSCRIPTION PRICE \$35.00
4. COMPLETE MAILING ADDRESS OF KNOWN OFFICE OF PUBLICATION (Street, City, County, State and ZIP+4 Code) (Not printers) 428 East Preston Street, Baltimore, Maryland 21202-3993			
5. COMPLETE MAILING ADDRESS OF THE HEADQUARTERS OF GENERAL BUSINESS OFFICES OF THE PUBLISHER (Not printers) 428 East Preston Street, Baltimore, Maryland 21202-3993			
6. FULL NAME AND COMPLETE MAILING ADDRESS OF PUBLISHER, EDITOR, AND MANAGING EDITOR (This item MUST NOT be blank)			
PUBLISHER (Name and Complete Mailing Address) Williams & Wilkins, 428 E. Preston St., Baltimore, MD 21202-3993			
EDITOR (Name and Complete Mailing Address) James A. Bain, Ph.D., School of Medicine, Emory University, 1440 Clifton Rd., NE, Atlanta, GA 30322			
MANAGING EDITOR (Name and Complete Mailing Address)			
7. OWNER (If owned by a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 1 percent or more of total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address, as well as that of each individual must be given. If the publication is published by a nonprofit organization, its name and address must be stated.) (Item must be completed.)			
FULL NAME American Society for Pharmacology and Experimental Therapeutics		COMPLETE MAILING ADDRESS 3650 ROCKVILLE PIKE Bethesda, MD 20814	
8. KNOWN BONDHOLDERS, MORTGAGEES, AND OTHER SECURITY HOLDERS OWNING OR HOLDING 1 PERCENT OR MORE OF TOTAL AMOUNT OF BONDS, MORTGAGES OR OTHER SECURITIES (If there are none, so state)			
FULL NAME NONE		COMPLETE MAILING ADDRESS	
9. FOR COMPLETION BY NONPROFIT ORGANIZATIONS AUTHORIZED TO MAIL AT SPECIAL RATES (Section 421, 12 DMN only) The purpose, function, and nonprofit status of this organization and the exempt status for Federal income tax purposes (Check one)			
<input checked="" type="checkbox"/> (1) HAS NOT CHANGED DURING PRECEDING 12 MONTHS		<input type="checkbox"/> (2) HAS CHANGED DURING PRECEDING 12 MONTHS (If changed, publisher must submit explanation of change with this statement.)	
10. EXTENT AND NATURE OF CIRCULATION (See instructions on reverse side)		AVERAGE NO. COPIES EACH ISSUE DURING PRECEDING 12 MONTHS	ACTUAL NO. COPIES OF SINGLE ISSUE PUBLISHED NEAREST TO FILING DATE
A. TOTAL NO. COPIES (Net Press Run)		3330	3252
B. PAID AND/OR REQUESTED CIRCULATION 1. Sales through dealers and carriers, street vendors and counter sales		74	72
2. Mail Subscriptions (Paid and/or requested)		2615	2467
C. TOTAL PAID AND/OR REQUESTED CIRCULATION (Sum of B1 and B2)		2689	2539
D. FREE DISTRIBUTION BY MAIL, CARRIER OR OTHER MEANS SAMPLES, COMPLIMENTARY, AND OTHER FREE COPIES		57	54
E. TOTAL DISTRIBUTION (Sum of C and D)		2746	2593
F. COPIES NOT DISTRIBUTED 1. Office use, left over, unaccounted, spoiled after printing		584	659
2. Return from News Agents		NONE	NONE
G. TOTAL (Sum of E, F1 and 2 - should equal net press run shown in A)		3330	3252
11. I certify that the statements made by me above are correct and complete		SIGNATURE AND TITLE OF EDITOR, PUBLISHER, BUSINESS MANAGER, OR OWNER Publisher <i>Alvin J. Wilks</i>	

Index

Pharmacological Reviews

Volume 39

1987

- Accidents, risk of, benzodiazepine use, 308
Aceprometazine, share of world market (table), 326
Acetaminophen, absolute *versus* normalized clearance, 7
Acetylhydrolase, acyltransferase and, inactivation, platelet-activating factor, 101
Acetyltransferase, biosynthesis of platelet-activating factor, 100
Adenylate cyclase, β -receptors, 84
Adrenoceptors, distribution, 50
Aggression, abuse liability of benzodiazepines, 317
Aging
 benzodiazepine use, 297
 interview studies of prevalence of use (table), 366
 learning and recall, benzodiazepines, 307
 prevalence of use in hospitals (table), 366
 prevalence of use in long-term care institutions (table), 368
 twelve-month prevalence of use, antianxiety/sedative agents (table), 365
Agonists
 comparisons, 277
 dose, benzodiazepines, 276
 opioid receptor, potency, 199
 response and concentration (fig.), 200
 mixtures, 216
 potency in GPI and MVD preparations (table), 210
 removal from bathing fluid, 218
 tissue receptor density (fig.), 201
Albumin, receptor model, 24
Alcohol, drivers detained while driving intoxicated (table), 311
Alcoholics
 outpatients, benzodiazepines, 266
 use of benzodiazepines, 375
Aldosterone, blood *versus* plasma clearance, 5
Allergy, skin diseases, platelet-activating factor, 117
[D-Ala²]Met-enkephalinamide, opioid receptor binding (fig.), 224
Alprazolam
 psychomotor performance
 elderly subjects (table), 298
 insomnia (table), 296
 repeated doses (table), 293
 share of world market (table), 326
Amnesia
 benzodiazepines, 300
 retrograde, 304
Amobarbital
 abuse liability of benzodiazepines, 259
 share of world market (table), 326
AMP, cyclic
 catecholamine action on smooth muscle, 59, 79
 β -receptor activation, 84
Anaphylaxis
 cardiac, 114
 platelet-activating factor, 111
Anesthetics, hepatic clearance, model predictions, 19
Antagonists
 competitive antagonism, 203
 dose, benzodiazepines, 275
 opioid receptor, 202
Anxiety
 antianxiety/sedative drugs
 duration of regular daily use (table), 356
 twelve-month prevalence of use (table), 345
 benzodiazepines, 294
 psychomotor performance (table), 295
 recall, 305
Aorta, catecholamine action, smooth muscle, 71, 78, 83
Arteries
 basilar, 70
 carotid, 73, 78
 cerebral, 69
 coronary, 68, 78, 82, 86
 ear, 69, 70, 77
 mesenteric, 67, 71, 77, 86
 potassium efflux, 74
 pulmonary, 73
 renal, 68, 71
 saphenous, 69
 tail, 69, 71, 78
Aspirin, platelet-activating factor, 105
Assays
 opioid receptor
 autoradiographic techniques, 232
 bioassay, 199, 205, 207
 methodologies, 228
 radioreceptor, 219
Asthma, platelet-activating factor, 111
Atrial natriuretic factor, cyclic GMP synthesis and function, 183
Australia
 drug sales of benzodiazepines, 329
 physician survey, 335
Automobile accidents
 benzodiazepine use, 308
 fatally injured victims, 314
 nonfatally injured victims, 313
Autoradiography
 grain density (fig.), 233
 opioid receptor, 232
 μ receptors (fig.), 233
Barbiturates
 compared to diazepam, 264
 reversing withdrawal, benzodiazepines, 268
Behavior, social, benzodiazepines, 316
Benzodiazepines
 abuse liability, 254
 adverse behavioral consequences, 290
 change in prescribed daily dose (table), 359
 comparisons, 271
 coroners' reports, 382
 drug utilization review studies, 331
 duration of treatment, 271, 276

- Benzodiazepines** (*continued*)
- epidemiological studies, 310
 - factors predisposing to dependence, 283
 - fatalities associated with use, 383
 - high doses and psychomotor performance (table), 292
 - hospital admissions, 381
 - hospital cases, 378
 - human studies, physiological dependence, 278
 - intensive care unit admissions, 382
 - interview and questionnaire studies, 279
 - misuse and recreational use, 371
 - mortality, 385
 - patients' strategies if drug withdrawn (table), 363
 - patterns of use, 356
 - placebo-controlled studies, 280
 - psychomotor performance, 290
 - psychotropic drug purchases, 333
 - regional and hospital prescription sales (table), 332
 - regional and other surveys of consumption (table), 349
 - reinforcing behavior, 263
 - reviews of dependence, 285
 - shorter-acting, discontinuation, 282
 - surveys of consumption, 344
 - therapeutic doses (table), 291
 - tranquilizer use (fig.), 325
 - twelve-month prevalence of use (table), 345
 - withdrawal, 270
- Bilirubin**, blood *versus* plasma clearance, 7
- Blood**
- free fraction, hepatic extraction (fig.), 22
 - versus* plasma clearance, 5
- Blood flow**, model predictions, hepatic clearance (fig.), 17
- Braquet, P., T. Y. Shen, L. Touqui, and B. Vargaftig. B. Perspectives on platelet-activating factor research, 97**
- Bromazepam**, share of world market (table), 326
- Bülbring, Edith, and Tadeo Tomita. Catecholamine action on smooth muscle, 49**
- Buspirone**, alcohol dependence, 265
- Calcium**
- arteries and arterioles, 67
 - catecholamine action on smooth muscle, 59, 61, 62
 - channel blocking agents, 127
- Canada**, drug sales of benzodiazepines, 329
- Cancer**, chemotherapy, PAF-related phospholipids, 119
- Cardiac output**
- absolute *versus* normalized clearance, 7
 - clearance and first-pass effect, 9
 - hepatic clearance, model predictions, 18
- Catecholamine**, action on smooth muscle, 49, 52, 79
- CDP-choline cholinephosphotransferase**, biosynthesis of platelet-activating factor, 102
- Central nervous system**, platelet-activating factor, 117
- Centrifugation**, blood *versus* plasma clearance, 7
- CGS-8216**, plasma corticosterone, 274
- Chemotherapy**, cancer, PAF-related phospholipids, 119
- Chlordiazepoxide**
- abuse liability of benzodiazepines, 255, 256, 257
 - repeated doses and psychomotor performance (table), 293
 - reversal of barbital withdrawal, 269
 - share of world market (table), 326
- Chloroquine**, blood *versus* plasma clearance, 6
- Chromatin**, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, 157
- Circulation**, hepatic clearance, model predictions, 19
- Cirrhosis**, experimental, plasma PAF, 119
- Clearance**
- apparent, 2
 - approaches in pharmacology, 1
 - blood *versus* plasma, 5
 - first-pass effect, 8
 - fractional, 2
 - intrinsic, 2, 14, 15, 37
 - in vitro-in vivo prediction, 33
 - metabolic, 2
 - organ, 2, 3
 - rate of elimination and, 7
 - total, 2
- Cloazepate**, clotiazolam and, share of world market (table), 326
- Coagulation**, blood *versus* plasma clearance, 6
- Cocaine**, abuse liability of benzodiazepines, 259
- Corticosterone**, benzodiazepine antagonist CGS-8216, 274
- Criminals**, use of benzodiazepines, 375
- Cyclosporin**, blood *versus* plasma clearance, 5
- Dependence**, withdrawal, benzodiazepines, 270
- Desethylchloroquine**, blood *versus* plasma clearance, 6
- Diacylglycerol**, platelet-activating factor, 102
- Diazepam**
- absolute *versus* normalized clearance, 7
 - anxiety, 262
 - intermittent drug availability, 259
 - place preference in drug taking, 256, 257
 - psychomotor performance
 - insomnia (table), 296
 - elderly subjects (table), 298
 - repeated doses (table), 293
 - reinforcing effects, 265
 - self-administration, 258, 260
 - share of world market (table), 326
 - withdrawal signs (fig.), 272, 273
- Dioxin**: *see* 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin
- Dipotassium clorazepate**, responding, 258
- DNA**, genomic elements, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, 154
- Drug Abuse Warning Network**, benzodiazepines, 382
- Drug delivery**
- clearance and first-pass effect, 10
 - platelet-activating factor, 105
- Drug distribution**
- blood *versus* plasma clearance, 5
 - clearance and first-pass effect, 9
- Drug taking**, drug seeking and, benzodiazepines, abuse liability, 254
- Electrophysiology**, opioid receptors, 213
- Elimination**
- clearance approaches in pharmacology, 1
 - fractions, 31
 - hepatic
 - models (fig.), 13
 - site of drug administration (fig.), 9
 - in vitro-in vivo prediction, 33
 - rate, clearance and, 7
- Endothelial cells**
- PAF-induced amplification cycle (fig.), 110
 - platelet-activating factor, 109
- Endothelial-derived relaxant factor**, cyclic GMP synthesis and function, 183
- Epidemiology**, benzodiazepine use and misuse, 320
- Ergotamine**, share of world market (table), 326
- Escherichia coli***, cyclic GMP synthesis and function, 183
- Ethanol**, reversing withdrawal, benzodiazepines, 268
- Exercise**, hepatic clearance, model predictions, 18
- Flunitrazepam**
- psychomotor performance
 - effects of high doses (table), 292

- insomnia (table), 296
 - share of world market (table), 326
- Flurazepam
 - continuation of use, 263
 - insomnia, 261, 262
 - psychomotor performance
 - elderly subjects (table), 298
 - repeated doses (table), 293
 - responding, 259
 - share of world market (table), 326
- Food ingestion, hepatic clearance, model predictions, 18
- Gastrointestinal tract
 - catecholamine action on smooth muscle, 52, 79
 - ulceration, platelet-activation factor, 116
- Gliotoxin
 - chemical structures of PAF (fig.), 122
 - PAF antagonists, 126
- Glycerol ether
 - C₁ changes in glycerol backbone (table), 103
 - regioselective formation (fig.), 99
 - replacement of glycerol backbone, 105
- Glycerophosphocholine, metabolism of PAF, 119
- GMP, cyclic, synthesis and production, 163
- Great Britain, drug sales of benzodiazepines, 329
- Guanylate cyclase
 - isoenzymes, 163
 - physicochemical properties, 166
 - purification, 165
 - purification from various sources (table), 166
- Halazepam
 - intra-gastric self-administration, 258
 - psychomotor performance and elderly subjects (table), 298
- Heart, anaphylaxis, 114
- Hematocrit, blood *versus* plasma clearance, 6
- Heparin, blood *versus* plasma clearance, 5, 7
- Hepatic acinus, metabolite disposition, 32
- Hydroxyzine, share of world market (table), 326
- Hypnotics
 - exposure of adult populations (table), 325
 - frequencies of prescriptions (table), 322
 - market share (table), 328
- Ibuprofen, absolute *versus* normalized clearance, 7
- Iceland, drug sales of benzodiazepines, 329
- Ileum, opioid receptor activity, 207
- Immune response, platelet-activating factor, 118
- Inflammation, acute, platelet-activating factor, 111
- Insomnia
 - benzodiazepines, 285
 - abuse liability, diazepam, 261
 - learning and recall, 307
 - psychomotor performance (table), 296
- Intestine
 - catecholamine action on smooth muscle, 52
 - clearance and first-pass effect, 10
 - cyclic GMP function, model systems, 183
- Ireland, Northern, drug sales of benzodiazepines, 329
- Ireland, Republic of, drug sales of benzodiazepines, 329
- Isoproterenol, catecholamine action on smooth muscle, 52
- Katz, Jonathan L. *See* Woods et al., 251
- Ketazolam
 - psychomotor performance
 - insomnia (table), 296
 - elderly subjects (table), 298
- Kidney
 - clearance and first-pass effect, 9
 - clearance model, 27
 - organ clearance, 2
 - platelet-activating factor
 - physiology and immune disorders, 114
 - transplant rejection, 113
- Learning, state-dependent, benzodiazepines, 305
- Leslie, Frances M. Methods used for the study of opioid receptors, 197
- Leukocytes, platelet-activating factor, 108
- Lidocaine
 - absolute *versus* normalized clearance, 7
 - liver blood flow, 19
- Life span, maximum potential, clearance and elimination, 37
- Lignans
 - chemical structures of PAF (fig.), 121, 124
 - PAF-antagonist activity (table), 125
- Liver
 - clearance and first-pass effect, 9, 10
 - clearance model, 12
 - organ clearance, 2
 - uptake, bound drug, 24
- Lorazepam
 - absolute *versus* normalized clearance, 7
 - insomnia, 261
 - repeated doses and psychomotor performance (table), 293
 - self-administration, 258
 - share of world market (table), 326
- Lung
 - clearance and first-pass effect, 9
 - organ clearance, 2
- Mammals, clearance and elimination, 35
- Mental retardation, drug use, 370
- Meprobamate, share of world market (table), 326
- Metabolites
 - chemically reactive, 33
 - clearance, 28
 - "fraction metabolized", 29
- Methadone, use of diazepam, 374
- Methyl transferase, biosynthesis of platelet-activating factor, 102
- Midazolam
 - abuse liability of benzodiazepines, 255
 - psychomotor performance and insomnia (table), 296
- Models
 - comparisons and discrimination, 26
 - dispersion, 14
 - distributed sinusoidal perfusion, 14
 - hepatic clearance predictions, 15
 - hepatic elimination (fig.), 13
 - parallel-tube, 13
- Murad, Ferid. *See* Waldman and Murad, 163
- Muscle
 - anococcygeus, catecholamine action, 64
 - nonvascular, 85
 - vascular, 85
- Muscle, smooth
 - airway, 80
 - catecholamine action, 49, 50, 86
 - cyclic GMP function, 187
 - spike action, 59
 - vascular, 66, 82
- Myometrium, catecholamine action, 52, 81
- Naloxone
 - opioid receptor terminology, 199

- Naloxone (*continued*)
 potencies of opioid agonists (table), 210
- Nerve stimulation, norepinephrine release, 69
- Neurotransmitter, release, opioid effects (table), 212
- New Zealand, benzodiazepine pattern of use, 358
- Nitrazepam
 psychomotor performance
 effects of high doses (table), 292
 elderly subjects (table), 298
 insomnia (table), 296
 repeated doses (table), 293
 share of world market (table), 326
- Nitro compounds, activation of guanylate cyclase, 172
- Nitroglycerin, cyclic GMP function, 187
- Nitrovasodilators, proposed mechanisms (fig.), 189
- Norepinephrine, nerve stimulation, 69, 74
- Normalization, absolute *versus* normalized clearance, 7
- Obesity, absolute *versus* normalized clearance, 7
- Opiates, studies of abusers, 374
- Opioids
 actions at peripheral neuroeffector junctions, 208
 dissociated cell preparations (table), 216
 ligands, binding selectivity profile (table), 217
 pharmacology, 198
- Ovoimplantation, platelet-activating factor, 118
- Oxazepam
 absolute *versus* normalized clearance, 7
 reinforcing effects, 265
 repeated doses and psychomotor performance (table), 293
 share of world market (table), 326
- PAF: *see* Platelet-activating factor
- Pentobarbital, abuse liability of benzodiazepines, 259
- Perfusion
 distributed sinusoidal, 14
 undistributed sinusoidal, 13
- Pharmacokinetics, future perspectives, 37
- Pharmacology
 clearance approaches, 1
 systemic effects of platelet-activating factor, 105
- Phenobarbital, share of world market (table), 326
- Phenytoin, blood *versus* plasma clearance, 7
- Phosphatidylinositol, platelet-activating factor, 102
- Phosphoinositides, α -action, 84
- Phospholipase A₂, biosynthesis of platelet-activating factor, 100
- Phospholipids
 PAF involvement, 133
 PAF-related, cancer chemotherapy, 119
- Phosphorylation, protein, cyclic GMP function, 187
- Phototransduction, retinal, cyclic GMP function, model systems, 185
- Physiological dependence, benzodiazepines, 267
- Plasma, *versus* blood clearance, 5
- Plasma membrane, catecholamine action, smooth muscle, 78
- Platelet-activating factor
 agonistic activity (fig.), 103
 antagonist activity of lignans (table), 125
 antagonists, 120
 biochemistry, 99
 cellular effects, 107
 effects on perfused organs and tissues, 106
 glossary of generic and chemical names (table), 131
 inactivation (fig.), 102
 metabolic cycle (fig.), 99
 metabolism, 101, 119
 perspectives, 97
 receptors, 127
 structure-activity relationship (table), 103, 105
 structure-activity relationship (fig., table), 104
 structures of antagonists (fig.), 121
 systemic, direct and indirect effects, 109
 thrombosis, 109
- Prazepam, share of world market (table), 326
- Prednisolone, absolute *versus* normalized clearance, 7
- Pregnancy
 drug use, 370
 platelet-activating factor, 118
- Prescriptions
 audits through the early 1950s (table), 323
 frequencies (table), 324
 sales, 324
- DL-Propranolol, hepatic clearance, model predictions, 19
- Protein
 binding, hepatic clearance, 21
 phosphorylation, cyclic GMP function, 187
- Radioligands
 adsorption, 231
 choice of, opioid receptor studies, 225
- Recall
 anxious subjects, 305
 benzodiazepines, 302
 effects of delay, 303
- Receptors
 opioid
 concentrations, 228
 experimental conditions control, 205, 225
 labeling *in vivo*, 236
 methods used for study, 187
 selective inactivation, 204
 selectivity, 203, 225
 solubilized, 229
 visualization, 237
 platelet-activating factor, 127
 2,3,7,8-tetrachlorodibenzo-*p*-dioxin
 biochemical properties, 150
 evidence, 148
 function, 152
- Retina, phototransduction, cyclic GMP function, model systems, 185
- Salicylic acid, blood *versus* plasma clearance, 7
- Secobarbital, abuse liability of benzodiazepines, 259
- Sedatives
 abusers, preference for benzodiazepines, 267
 duration of regular daily use (table), 356
 exposure of adult populations (table), 325
 frequencies of prescriptions (table), 322
 market share (table), 328
 twelve-month prevalence of use (table), 345
- Shen, T. Y. *See* Braquet et al., 97
- Shock, endotoxic and IgG-induced, 115
- Shunts, hepatic clearance, 21
- Skin, allergic diseases, platelet-activating factor, 117
- Sweden, benzodiazepine pattern of use, 358
- Taenia coli, catecholamine action, 52
- Temazepam
 psychomotor performance
 effects of high doses (table), 292
 elderly subjects (table), 298
 insomnia (table), 296
 repeated doses (table), 293
 share of world market (table), 326
- Terpenes, chemical structures of PAF (fig.), 121, 122

- 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin
formation (fig.), 148
gene expression regulation, 147
genomic elements (fig.), 154
- Tetrahydrofuran derivatives, PAF antagonists, 121
- Thermal stress, hepatic clearance, model predictions, 18
- Thiols, regulation of guanylate cyclase, 176
- Thrombosis, platelet participation, 109
- Tomita, Tadeo. *See* Bülbring and Tomita, 49
- Touqui, L. *See* Braquet et al., 97
- Trachea, catecholamine action, 63
- Tranquilizers
exposure of adult populations (table), 325
market share (table), 327
use among youth of three countries (table), 373
use by high school seniors (table), 372
- Transmitter, release studies, opioid receptor, 212
- Transplants, renal, rejection, platelet-activating factor, 113
- Triazolam
abuse liability of benzodiazepines, 256, 257
alcohol withdrawal, 264
insomnia, 262
psychomotor performance
elderly subjects (table), 298
insomnia (table), 296
share of world market (table), 326
- Triazolobenzodiazepines, PAF antagonism, 127
- United Kingdom
benzodiazepine pattern of use, 358
hospital use of benzodiazepines, 340
- United States
benzodiazepine pattern of use, 357
drug sales of benzodiazepines, 329
hospital use of benzodiazepines, 340
physician survey, 335
- Ureter, catecholamine action on smooth muscle, 61
- Vargaftig, B. B. *See* Braquet et al., 97
- Vas deferens
catecholamine action on smooth muscle, 60
opioid receptor activity, 210
- Vasodilators, cyclic GMP function, 187
- Veins
catecholamine action, smooth muscle, 75
facial, 78
mesenteric, 76
saphenous, 76, 78
- Verapamil, absolute *versus* normalized clearance, 7
- Waldman, Scott A. and Murad Ferid. Cyclic GMP synthesis and function, 163
- Warfarin, blood *versus* plasma clearance, 7
- White blood cells, blood *versus* plasma clearance, 6
- Whitlock, James P., Jr. The regulation of gene expression by 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, 147
- Wilkinson, G. R. Clearance approaches in pharmacology, 1
- Winger, Gail. *See* Woods et al., 251
- Withdrawal
barbital, suppression, 269
self-selected subjects, benzodiazepines, 281
spontaneous and precipitated, benzodiazepines, 275
- Woods, James H., Jonathan L. Katz, and Gail Winger. Abuse liability of benzodiazepines, 251
- Xenobiotics
clearance and first-pass effect, 8
clearance approaches in pharmacology, 1
interspecies differences, 35
- Zopiclone
alcohol withdrawal, 264
responding, 258